NCT01466985View on ClinicalTrials.gov

A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 21, 2011

Primary Completion Date

April 10, 2012

Study Completion Date

April 10, 2012

Conditions
HIV-1 Infection
Interventions
DRUG

Doravirine

Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).

DRUG

Placebo

Placebo tablets once daily for 7 days.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01466985 - A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005) | Biotech Hunter | Biotech Hunter